(Reuters) -U.S. drugmaker Pfizer on Wednesday launched a new multi-year program to reduce its expenses by about $1.5 billion by the end of 2027, adding on to a $4 billion cost cutting plan it ...

The company previously said its cost-cutting program would deliver overall net cost savings of roughly $4.5 billion by the end of 2025. On Tuesday, Pfizer said it now expects additional savings of ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it ...

Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential 29% upside. Click here to read.

Pfizer Expands Cost-Cutting Measures, Reaffirms Outlook. Company expects to save additional $1.2 billion from automation, AI and other digital tools. By . Jared S. Hopkins. and . Dean Seal.

The proposed cuts come as Pfizer works through a global campaign to cut costs by $4 billion by the end of 2024. In addition, Pfizer in May revealed a plan to cut additional costs out to 2027.

U.S. drugmaker Pfizer on Wednesday launched a new multi-year program to reduce its expenses by about $1.5 billion by the end of 2027, adding on to a $4 billion cost cutting plan it announced last ...

Pfizer still expects that changes to the Medicare program resulting from the Inflation Reduction Act will hurt sales by $1 billion, dampening growth by approximately 1.6% compared with 2024 ...

The company previously said its cost-cutting program would deliver overall net cost savings of roughly $4.5 billion by the end of 2025. On Tuesday, Pfizer said it now expects additional savings of ...

Pfizer on Tuesday expanded its cost-cutting efforts and reported first-quarter profit that topped estimates, even as the company's sales fell, largely due to dwindling revenue for its antiviral ...

Pfizer on Tuesday expanded its cost-cutting efforts and reported first-quarter profit that topped estimates, even as the company's sales fell, largely due to dwindling revenue for its antiviral ...